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Available online 6 February 2016Background: Adults with pulmonary arterial hypertension due to congenital heart disease (PAH-CHD) have a
poor prognosis. Identifying patients with a high risk for clinical events and death is important because their prog-
nosis can be improved by intensifying their treatment. Cystatin C, a novel cardiac biomarker, correlateswith right
ventricular dimensions in patients with idiopathic PAH, giving it potential to determine prognosis in PAH-CHD
patients. We investigated the predictive value of cystatin C for long-term mortality and clinical events.
Methods: Fifty-nine PAH-CHD patients (mean age 42 SD 13 years, 42% male) were included in this prospective
observational study, with cystatin C measurements between 2005 and 2015 on the outpatient clinic. Patients
were evaluated with a standardized evaluation protocol including laboratory, functional and echocardiographic
variables. Clinical events comprised worsening functional classiﬁcation, worsening heart failure, symptomatic
hyperviscosity, haemoptysis and arrhythmia. We used Cox regression to determine predictors for mortality
and clinical events.
Results: Mean follow-up was 4.4 years, during which 12 (20%) patients died. Cystatin C (HR 1.3, p b 0.001),
creatinine (HR 1.2, p b 0.001), NT-pro-BNP (HR 2.0, p = 0.012), hs-troponin T (HR 1.9, p = 0.005), 6-MWD
(HR 0.8, p= 0.044) and TAPSE (HR 0.8, p b 0.001) predictedmortality. Similar results were found for the predic-
tion of clinical events. When adjusted for NT-pro-BNP or glomerular ﬁltration rate in multivariate analysis,
cystatin C remained predictive for mortality.
Conclusions: Cystatin C, a novel cardiac biomarker, predicts long-term mortality and clinical events in patients
with PAH-CHD. Consequently, cystatin Cmay attribute to clinical decisionmaking regarding treatment intensity.
© 2016 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Keywords:
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Biomarkers1. Introduction
In congenital heart disease (CHD), the presence of pulmonary arteri-
al hypertension (PAH) is associated with poor prognosis [1–4]. PAH-
CHD is characterized by increased pulmonary vascular resistance
resulting in right ventricular (RV) remodeling, dysfunction and eventu-
ally failure. During this process, PAH-CHD patients are at risk for clinical
events such as hospitalization for heart failure, arrhythmias and ulti-
mately death.gy, Academic Medical Center,
rdam, The Netherlands.
eliability and freedom from bias
land Ltd. This is an open access articlIdentifying patients with a high risk for clinical events and death is
important because their prognosis can be improved by intensifying
their treatment [5]. Currently timing of initiation of PAH-speciﬁc combi-
nation therapy and determination of follow-up intensity depend on
parameters with an established association with mortality. These pa-
rameters, such as six-minutewalk distance (6-MWD) andWorldHealth
Organization (WHO) functional classiﬁcation, are formulated as treat-
ment goals in both the American and European PAH guidelines [6, 7].
However, the PAH guidelines are based on studies combining various
PAH etiologies, thus hampering its use in PAH-CHD patients speciﬁcally.
Within the last decade, biomarkers emerged as important prognostic
markers for clinical events and death in patients with PAH-CHD
[8–11]. Recently cystatin C, a novel cardiac biomarker, has been sug-
gested as potential prognostic biomarker in idiopathic PAH patients
[12]. Cystatin C correlates with RV pressures, function and morphology
[12] and reﬂects renal function [13], inﬂammation and vascular ande under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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CHD. Moreover, cystatin C is inexpensive, widely available, minimally
invasive and simple to determine [13]. However, its prognostic value
for patients with PAH-CHD is still not established.
In the current studywe investigated thepredictive value of the novel
cardiac biomarker cystatin C for long-termmortality and clinical events
in patients with PAH-CHD.
2. Methods
2.1. Study population
The current study was part of a prospective observational study on
PAH-speciﬁc therapy in adult patients with PAH-CHD [2], including
patients with Down syndrome [16, 17]. All PAH-CHD patients with
cystatin C measurements between March 2005 and July 2015 were
included, on the outpatient clinic of two tertiary referral centers. Both
patients with open or closed systemic-to-pulmonary shunts were in-
cluded. PAH was deﬁned upon the echocardiographic PAH probability
(tricuspid regurgitation velocity ≥2.9 m/s). Right heart catheterization
was only performed in case diagnosis of PAH was not clearly evident
at echocardiography. In patients who were PAH-therapy naïve,
bosentan or macitentan monotherapy was started. Eisenmenger syn-
drome, the most advanced stage of PAH-CHD, was deﬁned as a net
right-to-left shunt over the congenital heart defect due to an increased
pulmonary vascular resistance. Approval of the research protocol by
the local ethics committee was obtained. Informed consent was not re-
quired, as all investigations were performed for routine clinical care.
2.2. Data collection
Patients on the outpatient clinic were evaluated every three to six
months with a standardized evaluation protocol including laboratory,
six minute walk test and echocardiographic parameters. In order to
perform biomarker measurements at a later stage, blood obtained
from peripheral venous sampling was collected. This was stored in
a−80 °C frozen state until biomarker measurements were performed.
This stored blood was used in 30 (51%) patients for cystatin C and
high-sensitivity troponin T (hs-troponin T) measurements.
The six minute walk test was performed according to the American
Thoracic Society guidelines with continuous pulse oximetrymonitoring
[18]. Baseline echocardiography was performed with a Vivid 7 ultra-
sound system (General Electric). Pulmonary stenosis was ruled out in
all patients [19]. Tricuspid annular plane systolic excursion (TAPSE)
was measured in the lateral tricuspid valve annulus using M-mode in
the apical 4-chamber view. Right ventricular systolic pressure (RVSP)
was obtained from Doppler recording of tricuspid regurgitation using
the modiﬁed Bernoulli equation.
N-terminal pro brain natriuretic peptide (NT-pro-BNP) levels were
determined by electrochemiluminescence immunoassay on an Elecsys
2010 analyzer (Roche Diagnostics, Almere, The Netherlands). Hs-
Troponin T levelswere determinedwith an enzyme-linked immunosor-
bent assay method on the same analyzer. Cystatin C levels were deter-
mined with an immunonefelometry method on an ProSpec analyzer
(BN ProSpec, Siemens, Frimley, United Kingdom) using latex enhanced
particles coatedwith anti-cystatin C antibodies. The reference values for
young healthy persons range from 0.53 to 0.95 mg/l. The coefﬁcient of
variation was 1.8% within one run and 2.0% during reproducibility
tests. Freezing and long-term storage up to 25 years has a small impact
on stability of cystatin C [20].
2.3. Deﬁnition of clinical events
Clinical events comprised worsening WHO functional classiﬁcation,
worsening heart failure, symptomatic hyperviscosity, haemoptysis and
arrhythmia. Worsening heart failure was deﬁned as start or increaseof diuretics or hospital admission, for worsening symptoms of heart
failure. Arrhythmiaswere deﬁned as any episode of documented supra-
ventricular tachycardia that required electrocardioversion or change of
medication. Symptomatic hyperviscosity was deﬁned as two or more
symptoms of hyperviscosity (headache, faintness, dizziness, fatigue,
tinnitus, blurred vision, paraesthesia of ﬁngers, toes, and lips, muscle
pain, and weakness) in combination with an elevated hematocrit
(male 0.50 l/l, female 0.45 l/l).WorseningWHO functional classiﬁcation
was deﬁned as the ﬁrst increase inWHO classiﬁcation during follow-up
compared to the baseline value. Haemoptysiswas deﬁned as expectora-
tion of blood ranging from blood-streaking of sputum to the presence of
gross blood in the absence of any accompanying sputum.
2.4. Statistical analysis
Descriptive datawere presented asmean±SD if normally distribut-
ed or median with IQR, as appropriate. Categorical data were evaluated
using the chi-square statistic. The change of continuous variables was
evaluated using a 2-tailed paired t-test. Independent samples t-test or
Mann–Whitney U test was used for comparison of continuous variables
between two groups. Time to event analysiswasperformedwith Kaplan
Meier estimates of survival. Log rank test was performed to determine
signiﬁcant differences in mortality rate between two groups. Associa-
tions between predictors and outcomewere evaluated using univariate
Cox-regression analysis. The baseline visit was deﬁned as the evaluation
on the outpatient clinic during which cystatin C was measured. This
date was used as start date in the Cox analysis. Relevant cut-off for
cystatin C and NT-pro-BNP were obtained using a receiver operating
characteristics curve. All reported p values were two-sided, and values
of p b 0.05 were considered signiﬁcant. Statistical analysis was per-
formed with SPSS 22.0 (IBM Corp, Armonk, NY).
3. Results
3.1. Patient cohort
Fifty-nine adults (42 SD 13 years, 42%male) with PAH-CHDwere in-
cluded in the study. Table 1 summarizes the baseline characteristics. Of
all patients 41% had Down syndrome and 81% Eisenmenger syndrome.
Most patients had a normal renal function with a median creatinine of
80 μmol/l (upper limit of normal 110 μmol/l). Baseline therapy included
use of bosentan (20%), macitentan (17%), a combination of bosentan or
macitentan with sildenaﬁl (8%), or no PAH-therapy (55%). Following
baselinemeasurements, all of the therapy naïve patients startedwith ei-
ther bosentan or macitentan within two weeks, except for one patient
in whose case reimbursement of bosentan was rejected by the health
insurance. Mean follow-up was 4.4 years, during which 12 (20%)
patients died. Causes of death were right-sided heart failure (n = 6),
sudden cardiac death (n = 2), sepsis (n = 2), and unknown (n = 2).
Seven out of 24 patients with Down syndrome died during follow-up
compared to 5 out of 35 non-Down patients (p = 0.163). There were
several clinical events: fourteen patients had a worsening WHO func-
tional classiﬁcation, eight patients experienced arrhythmia, fourteen
had worsening heart failure (all patients received treatment with
diuretics), six had symptomatic hyperviscosity and six patients had
haemoptysis.
3.2. Predictors of outcome in PAH-CHD
Fig. 1 shows the predictors of outcome, including mortality and the
clinical events arrhythmia and worsening heart failure. An overview of
all predictors and clinical events is listed in supplementary Table 1.
Using univariate Cox-regression analysis, signiﬁcant determinants of
mortality were cystatin C (HR 1.3, p b 0.001), creatinine (HR 1.2,
p b 0.001), NT-pro-BNP (HR 2.0, p = 0.012), hs-troponin T (HR 1.9,
p = 0.005), 6-MWD (HR 0.8, p = 0.044) and TAPSE (HR 0.8,
Table 1
Baseline characteristics.
All patients
n = 59
Deceased
n = 12
Survivors
n = 47
p
Demographics
Age, years 42 SD 13 45 SD 11 41 SD 14 0.322
Male, n (%) 25 (42) 8 (67) 17 (36) 0.056
Down syndrome, n (%) 24 (41) 7 (58) 17 (36) 0.163
Clinical subgroup
Eisenmenger syndrome, n (%) 48 (81) 11 (92) 37 (79) 0.677
Systemic to pulmonary shunt, n (%) 4 (7) 0 (0) 4 (9)
Small defect, n (%) 1 (2) 0 (0) 1 (2)
Closed defect, n (%) 6 (10) 1 (8) 5 (11)
PAH-therapy
Bosentan monotherapy, n (%) 12 (20) 1 (8) 11 (23) 0.148
Macitentan monotherapy, n (%) 10 (17) 1 (8) 9 (19)
Combination ERA/PDE-5 inhibitor, n (%) 5 (8) 0 (0) 5 (11)
PAH-therapy naïve, n (%) 32 (55) 10 (83) 22 (47)
WHO functional class
WHO II, n (%) 26 (44) 5 (42) 21 (45) 0.851
WHO III, n (%) 33 (56) 7 (58) 26 (55)
WHO IV, n (%) 0 (0) 0 (0) 0 (0)
Laboratory
Cystatin C, mg/l 0.88 (0.79− 1.14) 1.19 (0.88− 2.03) 0.87 (0.78− 1.08) 0.004
High sensitive Troponin T, μg/l 0.008 (0.005− 0.017) 0.017 (0.007− 0.030) 0.006 (0.005− 0.015) 0.021
NT-pro-BNP, ng/l 430 (227− 1100) 827 (385− 2235) 339 (218− 959) 0.066
Creatinine, μmol/l 80 (67− 98) 98 (79− 154) 78 (67− 92) 0.005
Potassium, mmol/l 4.2 SD 0.4 4.5 SD 0.5 4.2 SD 0.4 0.010
ASAT, U/l 31 SD 10 37 SD 14 29 SD 8 0.078
CRP, mg/l 4.1 (2.2− 9.4) 3.1 (2.4− 9.2) 4.4 (1.6− 9.9) 0.800
Hemoglobin, mmol/l 11.2 SD 2.5 11.4 SD 2.7 11.1 SD 2.5 0.675
Echocardiography
Right ventricular systolic pressure, mmHg 83 SD 22 90 SD 14 81 SD 24 0.103
TAPSE, mm 19 SD 5 15 SD 5 20 SD 5 b0.001
Moderate or severely impaired LV function, n (%) 5 (9) 2 (17) 3 (6) 0.254
Exercise testing
Six-minute walking distance, m 379 SD 118 306 SD 115 398 SD 113 0.015
Resting arterial oxygen saturation, % 87 SD 7 84 SD 8 87 SD 7 0.188
Resting heart rate, bpm 80 SD 13 87 SD 14 78 SD 12 0.034
Data are mean ± standard deviation or median (IQR).
μg/l = microgram per liter; ng/l = nanogram per liter; mg/l = milligram per liter; ml/min = milliliter per minute; μmol/l = micromole per liter; U/l = units per liter.
PAH, pulmonary arterial hypertension; ERA, endothelin receptor antagonist; PDE-5, phosphodiesterase type 5; WHO, World Health Organization; NT-pro-BNP, N-terminal pro brain
natriuretic peptide; CRP, C-reactive protein; ASAT, aspartate aminotransferase; TAPSE, tricuspid annular plane systolic excursion; LV, left ventricular.
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NT-pro-BNP and hs-troponin T were predictive for all clinical events.
This accounted both for clinical events individually and for the com-
bined endpoint of any event.3.3. Cystatin C in PAH-CHD
Cystatin C was measured with a median level of 0.88 mg/l (upper
limit of normal 0.95 mg/l). Twenty-ﬁve patients had elevated cystatin
C levels (range 0.95 to 5.20 mg/l). Patients with Down syndrome were
more likely to have elevated levels of cystatin C (p = 0.010; Table S2).
Six minute walk distance (319 vs 424 m, p b 0.001) and estimated glo-
merular ﬁltration rate (52 vs 60ml/min/1.73m2, p b 0.001)were signif-
icantly lower in patients with elevated cystatin C compared to patients
with normal cystatin C levels. Finally, patients with elevated cystatin C
levels showed higher C-reactive protein levels (6.1 vs 2.9 mg/l, p =
0.002). The receiver operating characteristic analysis showed that a
cystatin C level of 1.10mg/l was the best cut-off value to predictmortal-
ity with a sensitivity of 67% and a speciﬁcity of 83% (area under the
curve (AUC) 0.77). Patients with cystatin C levels above the 1.10 mg/l
cut-off value showed a higher mortality rate (67% versus 36%, p =
0.001, Fig. 2). The best cut-off for NT-pro-BNP to predict mortality was
350 ng/l (sensitivity 83%, speciﬁcity 51%, AUC 0.67). A predicted survival
model on baseline cystatin C and NT-pro-BNP serum levels is shown in
Fig. 3. Patients with both a baseline cystatin C level above 1.10 mg/l and
NT-pro-BNP above 350 ng/l had amortality rate of 58% versus 11% in pa-
tients without both risk factors (log rank 16; p b 0.001). When adjustedfor NT-pro-BNP or glomerular ﬁltration rate in multivariate analysis,
cystatin C remained predictive for mortality (Table 2).
4. Discussion
4.1. Interpretation
The current study is the ﬁrst to indicate that the novel cardiac bio-
marker cystatin C predicts long-termmortality and clinical events in pa-
tientswith PAH-CHD. After dichotomizing for survival analysis based on
receiver operating characteristics, cystatin C above the optimal cut-off
(1.10 mg/l) was associated with a higher mortality rate (67% versus
36%, p = 0.001, Fig. 2). Cystatin C levels in our study were relatively
low (mean 1.08 mg/l) compared to studies on the effect of cystatin C
on mortality in acquired heart disease (mean 1.20–1.51 mg/l) [21–24],
presumably because our patient cohort was relatively young and had
preserved renal function. Similarities between these studies and the
current study were that, even with different cut-off points, all studies
found that increasing levels of cystatin C were associated with worse
survival. Additionally we showed cystatin C also predicts clinical events
such as arrhythmia and worsening heart failure.
It is well established that renal insufﬁciency predicts mortality in
PAH-CHD [11, 25, 26]. Because cystatin C is a sensitive indicator of
renal ﬁltration [13], it is conceivable cystatin Cmerely reﬂects renal dys-
function that by itself predicts mortality. However, cystatin C remained
predictive formortality after adjustment for glomerular ﬁltration rate in
multivariate analysis (Table 2). Moreover, three large studies, including
990, 480 and 279 patients with acquired heart disease, showed that
Fig. 1.Univariate predictors of outcome. To improve reader convenience all predictorswith a protecting effect on survivalweremultipliedwithminus one. Thus an increase of a predictor's
value equals a worse prognosis.
Fig. 2. Kaplan Meijer cystatin C above 1.10 mg/l.
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[21–23]. Other potential contributing mechanisms that could be
responsible for the prognostic role of cystatin C are the association be-
tween cystatin C and inﬂammation, direct role of cystatin C in the vascu-
lar wall remodeling in atherosclerosis and role in remodeling of heart
extracellular matrix [14, 15].
Cystatin C levels were higher in Down syndrome patients. The result
can be explained by multiple factors. Down syndrome patients in our
cohort had a more advanced PAH disease severity, indicated by higher
numbers of Eisenmenger syndrome, RVSP, and lower 6-MWD
(Table S2). PAH inﬂuences vascular wall remodeling [27]. More ad-
vanced PAH disease severity may have more effect on vascular wall re-
modeling, which could have increased cystatin C levels. Furthermore,
Down syndrome patients had a higher CRP (although non-signiﬁcant),
possibly indicatingmore inﬂammation. Lastly, Down syndromepatients
received PAH-speciﬁc combination therapy less frequently, which in
turn could have inﬂuenced disease severity. To our best knowledge, a
direct effect of PAH-speciﬁc therapy on cystatin C levels is unknown.Fig. 3. Predicted survival model based on cystatin C aThe development of PAH in patients with CHD is associated with in-
creased mortality and high morbidity [28]. However, it is believed that
the prognosis of patients with PAH-CHD can be improved by intensify-
ing their treatment. A recent study has shown that a more aggressive
approach using upfront combination therapy is more effective than
monotherapy [5]. Consequently, it is particularly important that simple
markers are identiﬁed that can risk-stratify patients to allow optimal
medical management. The PAH guidelines describe several treatment
goals which incorporate parameters with an established association
with prognosis [6, 7], but the guidelines are mainly based on studies
with idiopathic PAH patients. Since there are signiﬁcant differences in
pathophysiology and prognosis between PAH-CHD and idiopathic PAH
[29], it could well be that the effect size of the predictors for mortality
also differs.
4.2. Clinical impact
A recent study of Diller and coworkers in Eisenmenger patients chal-
lenged the traditional view of benign survival prospects of patients with
Eisenmenger syndrome and suggested a proactive treatment strategy
including a more aggressive approach trying to avoid the development
of the condition [30]. Traditionally, determination of follow-up intensity
and timing of initiation of PAH-speciﬁc combination therapy depended
on worsening of functional parameters such as 6-MWD and TAPSE. Our
data suggests that several simple biomarkers, next to these functional
parameters, can be used to evaluate prognosis of patients with PAH-
CHD. This way a timely start of aggressive treatment is possible and
disease progression might be delayed.
The use of multiple cardiac biomarkers is currently advocated in ac-
quired heart failure because it achieves greater predictive accuracy [31].
NT-pro-BNP is an already established biomarker of prognosis in patients
with PAH-CHD [6, 7]. In addition, we demonstrated the added value of
combining NT-pro-BNP with cystatin C. Our prediction model of NT-nd NT-pro-BNP serum levels. CysC = cystatin C.
Table 2
Multivariate analysis of cystatin C on mortality.
HR p
A
Cystatin C⁎a 1.3 0.009
NTproBNP⁎ 1.1 0.771
B
Cystatin C⁎a 1.2 0.028
MDRD GFR 1.0 0.749
A: multivariate analysis of cystatin C adjusted for NT-pro-BNP.
B: multivariate analysis of cystatin C adjusted for MDRD-GFR.
⁎ =log-transformed; a = per 0.1 mg/l; HR, Hazard ratio; NT-pro-BNP, N-terminal pro
brain natriuretic peptide; MDRD GFR, modiﬁcation of diet in renal disease glomerular
ﬁltration rate.
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cystatin C level above 1.10 mg/l and NT-pro-BNP above 350 ng/l had
higher mortality rates compared to patients without both risk factors,
which favors the use of multiple biomarkers. For the prediction of mor-
tality in PAH-CHD, we suggest the use of biomarkers which reﬂect dif-
ferent pathological pathways, for instance inﬂammation, volume
overload, RV and vascularwall remodeling. Cystatin C is an inexpensive,
widely available, minimally invasive and simple to determine laborato-
ry biomarkerwhich can give additional information about the prognosis
of patients with PAH-CHD.4.3. Limitations
A potential limitation was the relatively small study size, as in most
studies in patientswith CHD. Secondly, invasive hemodynamics are rec-
ommended in the guidelines for the diagnosis of PAH. However, echo-
cardiography is an adequate non-invasive modality in patients with
evident diagnosis of PAH [32] in patients with CHD. The vast majority
of patients (81%)had Eisenmenger syndrome.Due to thehigher compli-
cation risk in patients with PAH-CHD, cardiac catheterization was not
performed routinely in these patients. Patients with PAH-CHD often
have abnormal hemostasis, including thrombocytopenia, making them
at risk for both bleeding and thrombosis [33]. In particular, parietal
thrombosis of enlarged proximal pulmonary arteries can be found in
up to 20% of patients. Catheterisation in these patients may cause pe-
ripheral embolization and pulmonary infarctions, and is associated
with biventricular dysfunction and reduced pulmonary ﬂow velocity
[34]. Right heart catheterization was only performed at baseline in
case diagnosis of PAH was not clearly evident at echocardiography.5. Conclusion
Prognosis of adult PAH-CHD patients remains poor. Our study in
PAH-CHD patients showed that cystatin C, a novel cardiac biomarker,
predicts long-termmortality and clinical events. Consequently, cystatin
C may attribute to clinical decision making regarding treatment
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